PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsCenicriviroc
Cenicriviroc
Cenicriviroc is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target C-C chemokine receptor type 5.
Download report
Favorite
COVID-19
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver cirrhosisD008103EFO_0001422K74.0—1———1
FibrosisD005355———1———1
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81—1———1
Fatty liverD005234EFO_0003934——1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCenicriviroc
INNcenicriviroc
Description
Cenicriviroc is a member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). It has a role as a chemokine receptor 5 antagonist, an anti-HIV agent, a chemokine receptor 2 antagonist, an antirheumatic drug and an anti-inflammatory agent. It is a diether, a member of imidazoles, a sulfoxide, an aromatic ether, a secondary carboxamide and a benzazocine.
Classification
Small molecule
Drug classantivirals; antivirals, chemokine receptor (CCR) antagonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1
Identifiers
PDB—
CAS-ID497223-25-3
RxCUI—
ChEMBL IDCHEMBL2110727
ChEBI ID—
PubChem CID11285792
DrugBankDB11758
UNII ID15C116UA4Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CCR5
CCR5
Organism
Homo sapiens
Gene name
CCR5
Gene synonyms
CMKBR5
NCBI Gene ID
Protein name
C-C chemokine receptor type 5
Protein synonyms
C-C motif chemokine receptor 5 A159A, CD195, chemokine (C-C motif) receptor 5, chemokine receptor CCR5, chemokine recptor CCR5 Delta32, CHEMR13, HIV-1 fusion coreceptor, mutant C-C motif chemokine receptor
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,146 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
7 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use